Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.

Naber D, Kollack-Walker S, Chen J, Stauffer VL, Kinon BJ, Case M, Ascher-Svanum H, Kapur S, Kane JM.

Pharmacopsychiatry. 2013 May;46(3):114-9. doi: 10.1055/s-0032-1331703. Epub 2013 Jan 4.

PMID:
23293013
2.

Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM, Naber D.

Schizophr Res. 2010 May;118(1-3):176-82. doi: 10.1016/j.schres.2009.12.013. Epub 2010 Jan 15.

PMID:
20080036
3.

Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?

Tollefson GD, Andersen SW.

J Clin Psychiatry. 1999;60 Suppl 5:23-9; discussion 30. Review.

PMID:
10192404
4.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
5.

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA.

J Clin Psychiatry. 2006 Jul;67(7):1093-103.

PMID:
16889453
6.
7.

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.

Chen L, Phillips G, Johnston J, Kinon BJ, Ascher-Svanum H, Kollack-Walker S, Succop P, Naber D.

BMC Psychiatry. 2011 Dec 28;11:203. doi: 10.1186/1471-244X-11-203.

8.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
9.

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.

Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.

J Psychiatr Res. 2006 Oct;40(7):669-76. Epub 2006 Jun 9.

PMID:
16762371
10.

A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.

Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S.

Psychopharmacology (Berl). 2014 Feb;231(3):533-42. doi: 10.1007/s00213-013-3261-z. Epub 2013 Sep 8.

PMID:
24013610
11.

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S.

J Psychiatr Res. 2013 Apr;47(4):472-8. doi: 10.1016/j.jpsychires.2013.01.011. Epub 2013 Jan 30.

PMID:
23375406
12.
13.

Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.

Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S.

JAMA Psychiatry. 2015 Jan;72(1):14-21. doi: 10.1001/jamapsychiatry.2014.2127.

PMID:
25372935
14.

Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.

Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):703-12. Epub 2007 Jan 16.

PMID:
17289237
15.

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.

Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.

Eur Neuropsychopharmacol. 2014 Jun;24(6):846-55. doi: 10.1016/j.euroneuro.2014.02.001. Epub 2014 Feb 25.

PMID:
24636461
16.

The heterogeneity of antipsychotic response in the treatment of schizophrenia.

Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ.

Psychol Med. 2011 Jun;41(6):1291-300. doi: 10.1017/S0033291710001893. Epub 2010 Oct 7.

17.
18.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
19.

First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.

Popović I, Ravanić D, Popović V, Vladejić S, Stanojević A, Stojanović M.

Psychiatr Danub. 2011 Dec;23(4):384-8.

20.

Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.

Heres S, Don L, Herceg M, Bidzan L, Blanc M, Siracusano A, Maciulis V, Lahaye M, Schreiner A.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:207-12. doi: 10.1016/j.pnpbp.2013.09.015. Epub 2013 Oct 2.

PMID:
24096139
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk